Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

COVID-19: An Insight on the Third Respiratory Global Emergency of the Century

Author(s): Sonali Batra, Sumit Sharma*, Payal Verma and Nikhil Arora

Volume 2, Issue 3, 2021

Published on: 15 September, 2020

Page: [339 - 345] Pages: 7

DOI: 10.2174/2666796701999200915144814

Price: $65

Abstract

Introduction: COVID-19 presents a global emergency in recent days and as a consequence, the whole world is in a state of war. Continuous efforts by researchers are being made to establish a sound scientific understanding regarding the behavior of the virus and its pathogenesis.

Background: In recent days, a lot of scientific data are published describing viral transfusion into host cells, compared with SARS-CoV-1, viability of SARS-CoV-2, fatality and diagnosis of infection among infected patients, thereby, motivating to make right decisions in order to treat and mitigate COVID-19.

Review Results: Coronaviruses usually affect the respiratory tract and produce symptoms similar to pneumonia with varied complications. The spike protein on the surface of the virus makes the SARSCoV- 2 phylogenetically different from other viruses of the corona family. SARS-CoV-2 has an affinity to angiotensin converting enzyme-2 receptors present on human cells. The fatality of the disease is found to be low, but the severity of the disease might vary from person to person. The incubation period is 14 days but the symptoms like dry cough and high fever are evident around 3-7 days. Already known anti-inflammatory immunomodulators and antiviral drugs are being tested and still under clinical trials.

Conclusion: In this review, we are providing an insight into emergence of COVID-19 , its correlation with SARS-CoV-1 and the interpretation of global data representing the severity of unexpected dangers for humanity. Certain structural aspects and studies determining the viability of novel coronavirus have also been described. Moreover, case studies of recovered infected patients from COVID-19 explain the progression and patients’ pathophysiological conditions while suffering from the infection.

Clinical Significance: There are many current strategies which are being tried and practiced to overcome this pandemic disease apart from precautionary measures. Although now, some decline has been seen, but the question still remains the same of whether the scientists are approaching towards the clinical solution, or are still in the midstream. This requires more study and intensive research to finally come to a concrete conclusion.

Keywords: SARS-CoV-2, COVID-19, emergence, antigenicity, global statistics, coronaviruses.

Graphical Abstract

[1]
Gorbalenya AE, Baker S, Baric R, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5(4): 536-44.
[http://dx.doi.org/10.1038/s41564-020-0695-z] [PMID: 32123347]
[2]
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579(7798): 265-9.
[http://dx.doi.org/10.1038/s41586-020-2008-3] [PMID: 32015508]
[3]
Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J 2005; 24(11)(Suppl.): S223-7.
[http://dx.doi.org/10.1097/01.inf.0000188166.17324.60] [PMID: 16378050]
[4]
Tyrrell DAJ, Bynoe ML. Cultivation of a novel type of common-cold virus in organ cultures. BMJ 1965; 1(5448): 1467-70.
[http://dx.doi.org/10.1136/bmj.1.5448.1467] [PMID: 14288084]
[5]
Weiner LP. Coronaviruses: a historical perspective. InCoronaviruses. Boston: Springer 1987; pp. 1-5.
[http://dx.doi.org/10.1007/978-1-4684-1280-2_1]
[6]
Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17(3): 181-92.
[http://dx.doi.org/10.1038/s41579-018-0118-9] [PMID: 30531947]
[7]
Jingchun F, Liu X, Pan W, Douglas MW, Bao S. Epidemiology of 2019 Novel Coronavirus disease-19 in Gansu province, China, 2020. Emerging. Infect Dis J 2020; 26(6): 1257-65.
[http://dx.doi.org/10.3201/eid2606.200251]
[8]
Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005; 69(4): 635-64.
[http://dx.doi.org/10.1128/MMBR.69.4.635-664.2005] [PMID: 16339739]
[9]
Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and Coronaviruses. Viruses 2019; 11(1)E41
[http://dx.doi.org/10.3390/v11010041] [PMID: 30634396]
[10]
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367(6483): 1260-3.
[http://dx.doi.org/10.1126/science.abb2507] [PMID: 32075877]
[11]
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020; 181(2): 281-92.
[http://dx.doi.org/10.1016/j.cell.2020.02.058] [PMID: 32155444]
[12]
Mallapaty S. Why does the coronavirus spread so easily between people? Nature 2020; 579(7798): 183.
[http://dx.doi.org/10.1038/d41586-020-00660-x] [PMID: 32157230]
[13]
Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 2020; 176104742
[http://dx.doi.org/10.1016/j.antiviral.2020.104742] [PMID: 32057769]
[14]
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46(4): 586-90.
[http://dx.doi.org/10.1007/s00134-020-05985-9] [PMID: 32125455]
[15]
van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382(16): 1564-7.
[http://dx.doi.org/10.1056/NEJMc2004973] [PMID: 32182409]
[16]
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015; 1282: 1-23.
[http://dx.doi.org/10.1007/978-1-4939-2438-7_1] [PMID: 25720466]
[17]
Guan WJ, Ni Z, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032]
[18]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[19]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[20]
Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol 2020; 214108393
[http://dx.doi.org/10.1016/j.clim.2020.108393] [PMID: 32222466]
[21]
Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients With Coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77(6): 683-90.
[http://dx.doi.org/10.1001/jamaneurol.2020.1127] [PMID: 32275288]
[22]
Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. The Lancet Neurol 2020; 19(9): 767-83.
[http://dx.doi.org/10.1016/S1474-4422(20)30221-0]]
[23]
Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of Coronaviruses on the cardiovascular system: a review. JAMA Cardiol 2020; 5(7): 831-40.
[http://dx.doi.org/10.1001/jamacardio.2020.1286] [PMID: 32219363]
[24]
Chen L, Li Q, Zheng D, et al. Clinical characteristics of pregnant women with Covid-19 in Wuhan, China. N Engl J Med 2020; 382(25)e100
[http://dx.doi.org/10.1056/NEJMc2009226] [PMID: 32302077]
[25]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[26]
Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2019; 25(3)2000045
[http://dx.doi.org/10.2807/1560-7917.ES.2020.25.3.2000045]
[27]
Chu DKW, Pan Y, Cheng SMS, et al. Molecular diagnosis of a Novel Coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem 2020; 66(4): 549-55.
[http://dx.doi.org/10.1093/clinchem/hvaa029] [PMID: 32031583]
[28]
Xie X, Zhong Z, Zhao W, Zhang C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology 2020; 296(2)200343
[http://dx.doi.org/10.1148/radiol.2020200343]]
[29]
Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 Novel Coronavirus (2019-nCoV). Radiology 2020; 295(1): 202-7.
[http://dx.doi.org/10.1148/radiol.2020200230] [PMID: 32017661]
[30]
Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol 2020; 30(6): 3306-9.
[http://dx.doi.org/10.1007/s00330-020-06731-x.]
[31]
Guo Y-R, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res 2020; 7(1): 11-.
[http://dx.doi.org/10.1186/s40779-020-00240-0] [PMID: 32169119]
[32]
Jin Y-H, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020; 7(1): 4-4.
[http://dx.doi.org/10.1186/s40779-020-0233-6] [PMID: 32029004]
[33]
Holshue ML, DeBolt C, Lindquist S, et al. Washington State 2019-nCoV case investigation team. First case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[34]
Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA 2020; 323(14): 1335.
[http://dx.doi.org/10.1001/jama.2020.4344] [PMID: 32181795]
[35]
Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020; 55(5)105938
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105938] [PMID: 32171740]
[36]
Mingo RM, Simmons JA, Shoemaker CJ, et al. Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step. J Virol 2015; 89(5): 2931-43.
[http://dx.doi.org/10.1128/JVI.03398-14] [PMID: 25552710]
[37]
Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 1978; 75(7): 3327-31.
[http://dx.doi.org/10.1073/pnas.75.7.3327] [PMID: 28524]
[38]
Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6: 16.
[http://dx.doi.org/10.1038/s41421-020-0156-0] [PMID: 32194981]
[39]
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382(19): 1787-99.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[40]
Baden LR, Rubin EJ. Covid-19 - the search for effective therapy. N Engl J Med 2020; 382(19): 1851-2.
[http://dx.doi.org/10.1056/NEJMe2005477] [PMID: 32187463]
[41]
Clinicaltrials. Study to evaluate the safety and antiviral activity of remdesivir. Available from: https://clinicaltrials.gov/ct2/show/NCT04292730
[42]
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci 2017; 93(7): 449-63.
[http://dx.doi.org/10.2183/pjab.93.027] [PMID: 28769016]
[43]
Clinicaltrials. Favipiravir combined with tocilizumab in the treatment of corona virus disease. 2019. Available from: https://clinicaltrials.gov/ct2/show/record/NCT04310228
[44]
Clinicaltrials. Favipiravir tablets combine with chloroquine phosphate in the treatment of novel coronavirus pneumonia Available from: https://clinicaltrials.gov/ct2/show/record/NCT0431-9900? view=record

Rights & Permissions Print Cite
Article Metrics
12
1
© 2024 Bentham Science Publishers | Privacy Policy